Core Viewpoint - The company has initiated Phase I clinical trials for its quadrivalent and trivalent influenza virus subunit vaccines, specifically designed for individuals aged 65 and older, to enhance immune response and provide better protection against influenza [1] Group 1: Clinical Trials - The company has started Phase I clinical trials for its quadrivalent influenza virus subunit vaccine (adjuvanted) and trivalent influenza virus subunit vaccine (adjuvanted) [1] - The quadrivalent influenza virus subunit vaccine (adjuvanted) received approval for clinical trial application from the National Medical Products Administration of the People's Republic of China in July 2024 [1] - The trivalent influenza virus subunit vaccine (adjuvanted) obtained similar approval in October 2024 [1] Group 2: Target Population - The vaccines are specifically designed for the elderly population, particularly those aged 65 and above, who are at a higher risk of severe illness and death from influenza due to natural decline in immune function with age [1] - This demographic faces increased health impacts and economic burdens due to influenza infections [1] Group 3: Vaccine Features - The quadrivalent and trivalent vaccines include the MF59 adjuvant, which enhances immune response and increases antibody titers, providing better protection for the targeted age group [1]
中慧生物-B：四价流感病毒亚单位疫苗(佐剂)及三价流感病毒亚单位疫苗(佐剂)的I期临床试验启动